In their cohort, BRAF V600E mutation was not associated with any negative clinicopathologic factors except for age >45 years.17 These data corroborate findings in a large 459 patient study from the University of California, San Francisco, in which BRAF V600E mutation was also not associated with negative clinicopathologic factors.19 In a recent publication, BRAF V600E mutation did not worsen cancer‐specific mortality in patients <45 years old.20 Thus, the association of BRAF V600E mutation with aggressive PTC pathology and clinical recurrence remains unclear. The gene discussed is BRAF; the disease is cancer.